Table 1.
Characteristics of the study population by study status and randomization status
| Completed Study N=78 |
Withdrew N=16 |
P | Intervention Group N=53 |
Control Group N=25 |
P | |
|---|---|---|---|---|---|---|
| Current Age, Median (Range) | 12.7 (11.0-15.0) | 12.5 (11.3-14.9) | 0.96a | 12.8 (11.1-14.9) | 12.4 (11.0-15.0) | 0.21a |
| Age at Diagnosis, Median (Range) | 2.6 (0.0-11.3) | 4.9 (0.5-11.3) | 0.09a | 2.5 (0.0-11.3) | 3.1 (0.3-9.4) | 0.72a |
| Survival time, Median (Range) | 9.3 (2.4-14.3) | 7.8 (1.2-13.7) | 0.16a | 9.9 (2.4-14.3) | 8.7 (3.0-13.7) | 0.52a |
| Gender, N (%) | ||||||
| Female | 43 (55.1) | 4 (25.0) | 0.05b | 29 (54.7) | 14 (56.0) | 0.92c |
| Male | 35 (44.9) | 12 (75.0) | 24 (45.3) | 11 (44.0) | ||
| Race, N (%) | ||||||
| Black | 13 (16.7) | 5 (31.3) | 0.35b | 7 (13.2) | 6 (24.0) | 0.49b |
| White | 62 (79.5) | 11 (68.8) | 44 (83.0) | 18 (72.0) | ||
| Other | 3 (3.9) | 0 (0.0) | 2 (3.8) | 1 (4.0) | ||
| Diagnosis, N (%) | ||||||
| Acute lymphoblastic leukemia | 18 (23.1) | 6 (37.6) | 0.93b | 12 (22.6) | 6 (24.0) | 0.43b |
| Acute myeloid leukemia | 1 (1.3) | 0 (0.0) | 0 (0.0) | 1 (4.0) | ||
| CNS Tumors | 17 (21.8) | 3 (18.8) | 14 (26.4) | 3 (12.0) | ||
| Ewing Sarcoma | 1 (1.3) | 1 (6.2) | 1 (1.9) | 0 (0.0) | ||
| Germ cell tumor | 1 (1.3) | 0 (0.0) | 1 (1.9) | 0 (0.0) | ||
| Hodgkin lymphoma | 2 (2.5) | 0 (0.0) | 1 (1.9) | 1 (4.0) | ||
| Neuroblastoma | 6 (7.7) | 2 (12.6) | 3 (5.7) | 3 (12.0) | ||
| Non-Hodgkin lymphoma | 6 (7.7) | 1 (6.2) | 3 (5.7) | 3 (12.0) | ||
| Retinoblastoma | 11 (14.1) | 1 (6.2) | 9 (17.0) | 2 (8.0) | ||
| Rhabdomyosarcoma | 4 (5.1) | 1 (6.2) | 3 (5.7) | 1 (4.0) | ||
| Soft tissue sarcoma | 1 (1.3) | 0 (0.0) | 1 (1.9) | 0 (0.0) | ||
| Wilms tumor | 6 (7.7) | 1 (6.2) | 4 (7.6) | 2 (8.0) | ||
| Other malignancy | 4 (5.1) | 0 (0.0) | 1 (1.9) | 3 (12.0) | ||
| Treatment, N (%) | ||||||
| Surgery | 73 (93.6) | 15 (93.8) | 0.98c | 49 (92.5) | 24 (96.0) | 0.55c |
| Chemotherapy | 63 (80.8) | 13 (81.3) | 0.96c | 43 (81.1) | 20 (80.0) | 0.91c |
| Radiation | 29 (37.2) | 7 (43.8) | 0.62c | 19 (35.9) | 10 (40.0) | 0.72c |
| Physical Activity | ||||||
| Baseline Weekly MVPA, Mean minutes (SD) | 183.0 (98.5) | 158 (113.5) | 0.37d | 175.0 (101.9) | 200.2 (90.6) | 0.29d |
| Baseline Weekly MVPA, Median minutes (Range) | 168.6 (0.0-366.3) | 146.6 (0.0-336.7) | 0.39a | 161.7 (0.0-361.2) | 193.4 (0.0-366.3) | 0.28a |
a
Wilcoxon test
b
Fishers exact test
c
Chi-square test
d
T-test